Grindeks informs that the company participates in the leading pharmaceutical exhibition “CPhI Worldwide 2011”, October 25 – 27 in Frankfurt, Germany. During the exhibition Grindeks will meet its existing and potential new business partners. Grindeks stand is placed in the exhibition hall 4.2 with a number 42B40.

Grindeks has invested more than 32 millions lats in modernizing its facilities and developing company’s infrastructure over the last five years.  The company has opened a new final dosage forms (FDF) plant and a new active pharmaceutical ingredients (APIs) manufacturing unit, and carried out other significant projects. It brings a sustainable competitive advantage to the company to offer world class services and solutions.

Bringing together APIs and FDF capabilities, vertically integrated manufacturing approach is a strategic priority at Grindeks. The company offers solutions, where the know-how and expertise of complicated multi-stage APIs development, FDF development and manufacturing capacities are synergetic.

In its exhibition stand Grindeks will promote cooperation in three main business fields:

  • Research, development, manufacturing and sales of APIs
  • Full service of contract-manufacturing of FDF – development of activities in performing FDF, validation of the manufacturing process and analysis methods, development of drug registration documentation and manufacturing of different technologies of FDF
  • Registration and marketing services

Chairman of the Board of Grindeks Jānis Romanovskis: “We participate with a stand in this exhibition for the fourth consecutive year. It is the world’s leading pharmaceutical networking event, in which it is important to participate – to show that we are competitive among other pharmaceutical companies, to learn about the latest inventions, technologies and to stay informed about the latest pharmaceutical industry trends, and, of course, to use the advantages of the exhibition to meet with existing customers from all over the world and to build new business contacts. Experience from the previous years has shown that we are a stable participant of the global pharmaceutical market, we have our advantages and high-quality business solutions at affordable prices and we are assessed as a stable and reliable partner.”

„CPhI” is the world’s most important pharma event with 20 years of history. The exhibition brings together worldwide pharmaceutical manufacturers and other participants of industry.

About Grindeks

Grindeks is the leading pharmaceutical company in the Baltic States. Its main fields of action are: research, development, manufacturing and sale of original products, generics and active pharmaceutical ingredients. The Group of Grindeks consists of four subsidiary companies in Latvia, Estonia and Russia, as well representative offices in ten countries.

Grindeks specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups. A range of products covers a successful combination of original products and generics, with the original products Mildronate® and Ftorafur® and more than 100 forms of effective and safe generics included therein. Currently Grindeks produces 16 active pharmaceutical ingredients.

Products of the company are exported to 50 countries and its export comprises more than 95% of the total turnover. The main markets are: Russia and other CIS countries, the Baltic States, Germany and the Netherlands. In 2010 The Ministry of Economics of Republic of Latvia and Investment and Development Agency of Latvia awarded Grindeks as the most export potential company of Latvia. During the last years the company realized many considerable investment projects in purpose to increase production capacity and develop infrastructure and invested 32.7 million lats within five years.

JSC Grindeks shares are listed in the Official List of “Nasdaq OMX Riga”. Major shareholders of JSC Grindeks are Kirovs Lipmans – 33.29%, Anna Lipmane – 16.69%, “Skandinaviska Enskilda Banken” – 12.42%, “AB.LV Private Equity fund 2010” – 11.38%, “Swedbank” AS Clients Account – 6.87%.

Further information:
Laila Klavina
Head of the Communications Department, JSC Grindeks
Phones: (+371) 67083370, (+371) 29256012
Fax: (+371) 67083505